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Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to
half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including
CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Euro-
peans (hereafter collectively referred to as ‘Caucasians’). Only people with at least one CYP3A5*1 allele express large
amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that
cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5
was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because
CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5,
CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-depen-
dent drug clearance and in responses to many medicines.
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Introduction
A major goal of the Human Genome Project has been completed
with publication of the draft sequence of the human genome1,2.
Understanding the biological and medical implications of variation
in the human genome sequence is another major aim of the Human
Genome Project3,4. Cytochromes P450 (CYP) are particularly
amenable for rapid identification of functionally important
sequence variations, because CYP catalytic activities can be deter-
mined by various in vivo and in vitro drug bioassays. Moreover, the
applications of such information are particularly relevant for phar-
macogenomics, in which knowledge of SNPs in CYP genes may
lead to individualized drug dosing and improved therapeutics5.
Here we elucidate whether sequence variations in the promoters of
genes encoding enzymes of the CYP3A family contribute to vari-
ability in CYP3A metabolism.
The cytochromes P450 evolved to catalyze the metabolism of
numerous structurally diverse exogenous and endogenous mol-
ecules. Approximately 55 different CYP genes are present in the
human genome and are classified into different families and
subfamilies on the basis of sequence homology. The CYP fami-
lies have arisen through a process of gene duplication and gene
conversion. Members of the CYP3A subfamily catalyze the
oxidative, peroxidative and reductive metabolism of struc-
turally diverse endobiotics, drugs, and protoxic or procarcino-
genic molecules6. The CYP3A members are the most abundant
CYPs in human liver and small intestine7,8. Substantial
interindividual differences in CYP3A expression, exceeding 30-
fold in some populations9, contribute greatly to variation in
oral bioavailability and systemic clearance of CYP3A substrates,
including HIV protease inhibitors, several calcium channel
blockers and some cholesterol-lowering drugs. Variation in
CYP3A expression is particularly important for substrates with
narrow therapeutic indices, such as cancer chemotherapeutics10
and the immunosuppressants cyclosporin A and tacrolimus
(FK506). Such variation in CYP3A can result in clinically signif-
icant differences in drug toxicities (for example, nephrotoxic-
ity) and response (for example, graft survival). Moreover,
because CYP3A metabolizes estrogens to 2-hydroxyesterone, 4-
hydroxyestrone and 16α-hydroxylated estrogens, all of which
have been implicated in estrogen-mediated carcinogenicity11,
variation in CYP3A may influence the circulating levels of these
estrogens and the risk of breast cancer.
Human CYP3A activities reflect the heterogeneous expression
of at least three CYP3A family members: CYP3A4, CYP3A5 and
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CYP3A7. The CYP3A genes are adjacent to each other on chro-
mosome band 7q21, but the genes are differentially regulated12.
Two CYP3A pseudogenes, CYP3AP1 and CYP3AP2, were recently
identified12. Functional CYP3A4 is found in most adults, with 10-
to 40-fold variation in its expression. CYP3A7 is predominantly
expressed in fetal life, and its expression seems to be silenced
shortly after birth; however, some people express CYP3A7 mRNA
into adulthood13. CYP3A4 activity is correlated with CYP3A4
mRNA concentrations, indicating that transcriptional control is
the primary mechanism for regulating expression of CYP3A4.
CYP3A5 was previously detected in livers and small intestines of
some adult Caucasians, but the basis for this ‘polymorphic’
expression is unknown14–16. Recently, two mutations in what was
believed to be the CYP3A5 promoter were found to be associated
with polymorphic CYP3A5 expression17. Sequencing of the
CYP3A locus, however, revealed that these SNPs are actually in the
promoter of the pseudogene CYP3AP1 (ref. 12) and, thus, cannot
be the basis for polymorphic CYP3A5 expression. The CYP3A4,
CYP3A5 and CYP3A7 promoters contain multiple putative tran-
scription-factor–binding sites. In particular, a recently discovered
nuclear receptor, PXR/SXR (for pregnane X-receptor/steroid and
xenbiotic receptor), that binds to a PXR response element in the
CYP3A4 and CYP3A7 promoters is important for regulation of
the CYP3A proteins18,19. Therefore, we hypothesized that poly-
morphisms affecting CYP3A activity are present in DNA regula-
tory sequences. Through a systematic analysis of genomic DNA
from a large number of patients with various drug metabolism
phenotypes, and through analysis of DNA from the Coriell DNA
Polymorphism Discovery Resource (DPDR; ref. 3), we identified
all common variants in the promoter regions of CYP3A4,
CYP3A5, CYP3AP1 and CYP3A7, and demonstrated ethnic differ-
ences in allele frequencies. By performing quantitative
immunoblotting and in vitro kinetic assays of drug metabolism,
we evaluated the relationship between these common genetic
variants and ethnic- and tissue-specific phenotypic variability. In
addition, analysis of human liver CYP3A5 cDNA revealed that
only those people with a CYP3A5*1 allele produce high levels of
full-length CYP3A5 mRNA and express CYP3A5. Those with the
CYP3A5*3 allele have sequence variability in intron 3 that creates
a cryptic splice site and results in the generation of CYP3A5 exon
3B; this CYP3A5*3 allele encodes an aberrantly spliced mRNA
with a premature stop codon. This finding explains the molecular
defect responsible for one of the most common polymorphisms
in drug-metabolizing enzymes.
Results
We initially performed SNP analysis of the promoter regions of
the CYP3A genes on DNA from the smallest DPDR subset (Table
1). The minimum DPDR panel contained five variant alleles with
a frequency greater than or equal to 1% in the combined study
population. These variant alleles included the CYP3A4*1B allele,
in which an A→G variant at nt –288 is present in the nifedipine-
specific element of the promoter20. We detected the CYP3AP1*1
reference allele (G at nt –44 in the promoter) in 43 people (28
heterozygotes and 15 homozygotes). In an unusual haplotype,
hereafter referred to as CYP3A7*1C (Table 1), an approximately
60-bp stretch (nt –129 to –188) of the CYP3A7 promoter seems
to have been replaced with sequence identical to the same region
in the CYP3A4 promoter. This replacement indicates the occur-
rence of a gene conversion event21.
The Coriell DPDR panel was designed to represent the genetic
diversity of United States residents who have ancestors from
Europe, Africa, the Americas and Asia. We found no variants in
the DPDR panel that were not also seen in the combined study
population, but additional CYP3A alleles found in our larger
combined population were not present in the DPDR. Most of
these alleles were rare (that is, they were seen in only one or two
people). To assess the usefulness of the DPDR panel in predicting
SNPs, we calculated the probability that common variants would
be missed in a random sampling of our combined population.
The chance of missing the polymorphic alleles CYP3A4*1B and
CYP3AP1*1 was less than 5%, even if the sample consisted of as
few as 10 study subjects from the combined population group. If
we were to randomly select a sample of 25 subjects, the probability
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Fig. 1 Splice variants of CYP3A5. 
a, Schematic drawing of the cDNA
structures of the various CYP3A5 alle-
les. Exons are numbered and boxed,
and primers P11 (exon 2/3) and P6
(exon 8) are indicated. The location of
intronic sequences coding for exons
3B, 4B and 5B derived from intron
sequences are indicated as filled
boxes. b, RT–PCR analysis of mRNAs
encoded for by the various CYP3A5
alleles. Total mRNA from human livers
was reverse transcribed and amplified
using PCR primers P11 (exon 2/3) and
P6 (exon 8) and the products analyzed
on agarose gels. CYP3A5 cDNA was
amplified by 30 and 35 cycles of
RT–PCR from hepatic RNA of people
expressing high and low amounts of
CYP3A5 protein, respectively. The PCR
product of CYP3A5*1 is the expected
size of 539 bp; the CYP3A5*6 mRNA
lacking exon 7 is 391 bp; the normally
spliced CYP3A5*3 mRNA (539 bp) (wt)
and the CYP3A5*3 SV1 mRNA con-
taining exon 3B (670 bp) and SV2
mRNA containing exon 3B and 4B
(775 bp) and the SV3 mRNA contain-
ing exons 3B, 4B and 5B and missing
exon 6 (769 bp). The CYP3A5*1/*1,
CYP3A5*1/*3 and CYP3A5*3/*3 geno-
types (AA, AG and GG, respectively, at
nt 22,893 in CYP3A5 (AC005020)).
a
b
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of missing polymorphic CYP3A7*1C alleles would be 15%, that of
missing CYP3A7*1E would be 25%, and that of missing
CYP3A7*1D would be greater than 60%. The probability of miss-
ing the rare alleles CYP3A4*1C, CYP3A4*1D, CYP3AP1*1B and
CYP3AP1*1C would be greater than 60%. Thus the DPDR 8-sam-
ple subset was more useful in accurately predicting the identity of
CYP3A SNPs than a random sampling of 25 people from the com-
bined population.
As has been previously reported22, CYP3A4*1B occurred at a
much higher frequency in African Americans (q=0.35) than in
Caucasians (q=0.02; χ2=48.9, P<0.001). We found no SNPs in
the regions containing the proximal (nt –169 to –152) and distal
(nt –7836 to –7208; ref. 23) PXREs of CYP3A4. Sequence analysis
of the CYP3A5 promoter (nt +90 to –280) revealed two SNPs in
the 5´ UTR (Table 1). CYP3A7*1C was three times more common
in an African American population (q=0.06) than in a Caucasian
population (q=0.03). Among the 10 unrelated French Caucasians
in the study, however, 3 people were heterozygous for
CYP3A7*1C (q=0.15), whereas only 2 of the 96 unrelated non-
French Caucasians carried 1 CYP3A7*1C allele (q=0.01).
CYP3AP1*1 was the most common minor allele in Caucasians
and African Americans. This allele is also divergently distributed
among African Americans (q=0.50) and Caucasians (q=0.08,
χ2=51.1, P<0.001). By examining other panels of DNA, we found
that the frequency of CYP3AP1*1 alleles (q values) in Japanese
was 0.15; in Chinese, 0.3; in Mexicans, 0.13; in Southeast Asians
(excluding Japanese and Chinese), 0.5; in Pacific Islanders, 0.3;
and in Southwestern American Indians, 0.5.
We determined the association of CYP3A alleles with CYP3A
phenotypes. None of the SNPs in the CYP3A5 or CYP3A4
promoters, including the CYP3A4*1B allele, were associated with
altered CYP3A activities of people whose phenotypes had been
determined in vivo by the erythromycin breath test or nifedipine
clearance or in vitro by assays for total midazolam hydroxylase or
for basal or rifampin-inducible testosterone 6β-hydroxylase activ-
ity. Previous studies have noted the polymorphic expression of
CYP3A5 in the liver and intestine of approximately 25% of people
studied14,16,24. Although there is good concordance of CYP3AP1*1
(G at nt –44) with high levels of CYP3A5 in the liver17, CYP3AP1*1
cannot be responsible for polymorphic CYP3A5 expression.
Because we did not find a CYP3A5 promoter variant that correlated
with CYP3A5 expression, we determined whether CYP3AP1*1 was
in linkage disequilibrium with another variant in CYP3A5 that
might be causal. Because the CYP3AP1 genotype is correlated with
CYP3A5 expression17, we used mRNAs from Caucasian and
African American livers representing the CYP3AP1*1/*1,
CYP3AP1*1/*3 and CYP3AP1*3/*3 genotypes to generate and
sequence the entire CYP3A5 cDNA. The CYP3A5 mRNA content
was greater in people with a CYP3AP1*1 allele than in those people
homozygous for CYP3AP1*3. All livers contained the full-length
CYP3A5 mRNA transcript encoded by CYP3A5*1 (Fig. 1). Many
people carrying CYP3AP1*3 also carried CYP3A5*3, which encodes
only a small amount of normally spliced CYP3A5 mRNA and a
splice variant-1 (SV1) mRNA. SV1 results from a SNP at nt 22,893
(in AC005020), which creates a cryptic consensus splice site and
exon 3B, an exon derived from intron-3 sequences of CYP3A5 (Fig.
1 and Table 2). The mutated sequence in intron 3 of CYP3A5*3 has
a splice site prediction score of 0.9. Because of the premature termi-
nation codon in exon 3B, the SV1 mRNA encodes a protein whose
sequence is truncated after amino acid 102. We found a second
Table 1 • Frequencies of SNPs in CYP3A promoters
Name of DPDRa Combined populationb Caucasiansc African Americansd Effect of
variant Reference Variant reference variant reference variant reference variant reference variant variant
Gene Location allelee allele allele allele allelef allele allelef allele allelef allele allelef Region allele
CYP3A4g –341 CYP3A4*1C Tggga Gggga 1.00 0.00 0.99 0.00 0.99 0.01 1.00 0.00
–288 CYP3A4*1Bh ggcaAgaga ggcaGgaga 0.81 0.19 0.87 0.13 0.98 0.02 0.65 0.35 NFSE
+43 CYP3A4*1D ccagCaaag ccagAaaag 1.00 0.00 0.99 0.00 0.99 0.01 1.00 0.00
CYP3AP1g,h–117 CYP3AP1*1B ttccCcata ttccTcata 1.00 0.00 0.99 0.01 1.00 0.00 0.97 0.03
–109 CYP3AP1*1C agaaTatga agaaCatga 1.00 0.00 0.99 0.01 1.00 0.00 0.97 0.03
–44 CYP3AP1*3 ccccGcctc ccccAcctc 0.38 0.62 0.22 0.78 0.08 0.92 0.50 0.50 Sp1 associated with
decreased hepatic 
and intestinal
CYP3A5 protein
CYP3A7g –211 CYP3A7*1B actcCccag actcTccag 1.00 0.00 0.99 0.00 0.99 0.01 1.00 0.00
–188 CYP3A7*1Ci ttgtGtatg ttgtTtatg 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06 HNF-5 enhanced
3A7 mRNA
after birth
–181 CYP3A7*1Ci tgatTctac tgatAcctc 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06
–179 CYP3A7*1Ci attcTacat attcCacat 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06
–178 CYP3A7*1Ci ttctAcata ttctTcata 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06
–167 CYP3A7*1Ci atatTaact atatGaact 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06 PXR-RE
–159 CYP3A7*1Ci tcaaTggag tcaaAggag 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06 PXR-RE
–129 CYP3A7*1Ci gattAtttg gattCtttg 0.87 0.13 0.96 0.04 0.97 0.03 0.94 0.06 octamer motif
+13 CYP3A7*1D gcagGgcag gcagAgcag 0.94 0.06 0.99 0.01 0.99 0.01 1.00 0.00
+55 CYP3A7*1E gcacGctgc gcacActgc 0.94 0.06 0.97 0.03 1.00 0.00 0.92 0.08
CYP3A5 +18 CYP3A5*1B gcagGgaag gcagAgaag NA NA 0.98 0.02 0.97 0.03 1.00 0.00
+30 CYP3A5*1C caggCaaac caggTaaac NA NA 0.96 0.04 0.97 0.03 0.93 0.07
aAnalyzed people=8. bAnalyzed people analyzed people=119 (CYP3A4/7), 123 (CYP3A5P1) or 74 (CYP3A5). cAnalyzed people=79 (CYP3A4/7), 83 (CYP3A5P1) or 59
(CYP3A5). dAnalyzed people=40 (CYP3A4/7/P1) or 15 (CYP3A5). eThe CYP alleles are named according to recommended nomenclature guidelines44
(http://www.imm.ki.se/CYPalleles). fThe frequency of the variant alleles was calculated by using the formula: frequency = [2*(number of people homozygous for
the variant allele)+(the number of heterozygous people)]/[2*(total number of people)]. The frequency of the reference allele was equal to the following: 1–(vari-
ant allele frequency). For DNA from families, we included only data gathered from the parents’ samples in the frequency calculations. gThe CYP3A4*1, CYP3A7*1
and CYP3A5*1 reference alleles are D11131, AF280107 and AC005020, respectively. Apparent errors in the original sequence of the CYP3AP1 promoter are cor-
rected and deposited as the consensus sequence for CYP3AP1*1. The variants are numbered relative to the initiation site of transcription, which is defined as +1.
To renumber alleles according to the translation start site (A in initiation codon ATG is +1), subtract 103 bases from the SNP location (for example, the location of
CYP3AP1*3 changes from –44 to –147). hCYP3A4*1B and CYP3AP1*1 are partially linked in African Americans. iThese seven CYP3A7 variants (hereafter referred
to as CYP3A7*1C) are located between nt –129 and –188 and are in complete linkage.
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splice variant (SV2) mRNA that encoded exons 3B and 4B in many
people carrying CYP3A5*3. Although sequence analysis around the
predicted splice site for exon 4B revealed a SNP at nt 24,035 (Table
2), this SNP and the generation of SV2 were not related (Table 2). A
third splice variant (SV3) mRNA comigrated with SV2 in an
agarose gel (Fig. 1) and contained exons 3B, 4B and 5B, but not
exon 6. No SNPs were found around exon 5B or exon 6 that corre-
lated with the SV3 transcript. The fact that mRNAs with premature
stop codons are more unstable and rapidly degraded25 may explain
the lower amount of CYP3A5 mRNA in people homozygous for
CYP3A5*3 compared with people carrying at least one CYP3A5*1
allele. We examined the frequency of the CYP3A5*1 allele and
found it to be distributed divergently among African Americans
(q=0.45) and Caucasians (q=0.15). By examining other panels of
DNA, we found that the frequency of CYP3A5*1 alleles (q values) in
the DPDR subset of 8 people was 0.31; in Japanese, 0.15; in Chinese,
0.35; in Mexicans, 0.25; in Southeast Asians (excluding Japanese
and Chinese), 0.33; in Pacific Islanders, 0.35; and in Southwestern
American Indians, 0.6. CYP3A5*6 was identified in only 3 of 20
African Americans and encoded a normal CYP3A5 mRNA and a
splice variant mRNA in which exon 7 was deleted. This deletion
resulted in a frameshift, causing the encoded protein to be trun-
cated at amino acid 184. Sequence analysis of genomic DNA and
cDNA synthesized from the spliced variant mRNA from those indi-
viduals skipping exon 7 identified a single sequence variation: a
30597G>A synonymous mutation in exon 7 (nt 711 G>A in the
CYP3A5 cDNA). This genotype was concordant with the loss of
exon 7. This silent mutation may cause exon 7 skipping by disrupt-
ing an exonic splicing enhancer26.
To determine the association of the CYP3A5 and CYP3AP alle-
les with CYP3A5 expression, we measured CYP3A5 protein con-
centration in liver specimens. We found a greater frequency of
CYP3A5 (≥21 pmol/mg protein) in African Americans (11/20;
50%) compared with Caucasians (9/27; 33%). All Caucasians
and most African Americans with a CYP3A5 content less than 21
pmol/mg protein were homozygous for the CYP3A5*3 allele with
G at nt 22,893 leading to cryptic CYP3A5 mRNA splicing,
whereas those with CYP3A5 content ranging from 21 to 202
pmol/mg had at least one CYP3A5*1 allele (A at nt 22,893 with
no aberrant CYP3A5 mRNA splicing; Fig. 2a,b). Among the livers
of Caucasians, the CYP3A5 allele frequencies conformed to
Hardy–Weinberg equilibrium. There was also complete concor-
dance between the CYP3A5*1 and CYP3AP1*1 genotypes and
between CYP3A5*3 and CYP3AP1*3 genotypes in Caucasians.
Among African Americans, however, there were several outliers
when the CYP3AP1 genotype was used to predict African Ameri-
can CYP3A5 phenotype. Specifically, African American liver 788
had a relatively high level of CYP3A5 (54 pmol/mg protein) that
was not predicted by a CYP3AP1*3/*3 genotype, but was
explained by the CYP3A5*1/*3 genotype. African American livers
624 and 958.29 had relatively low levels of CY3A5 protein that
were not predicted by a CYP3AP1*1/*1 genotype, but were better
explained by CYP3A5*1/*6 genotypes because the CYP3A5*6
allele generates an mRNA lacking exon 7. The final outlier
(African American liver 50) had only a trace amount of CYP3A5
protein that was not predicted by the CYP3AP1*1/*3 genotype or
the CYP3A5*1/*3 genotype. This discrepancy may be due to sec-
ondary degradation of CYP3A5 and other proteins following
poor tissue preservation, or to a second mutation in the coding
region of CYP3A5 that confers instability of the protein (for
example, CYP3A5*2; ref. 27).
We examined the rates of midazolam hydroxylation by the
same 47 livers. CYP3A4 and CYP3A5 each produce two metabo-
lites: 1´-hydroxymidazolam (1´-OH MDZ) and 4-hydroxymida-
zolam (4-OH MDZ). The mean reaction velocities were 2.5-fold
(P=0.03) higher for the livers of Caucasians and 2.2-fold
(P=0.19) higher for the livers of African Americans with at least
one CYP3A5*1 allele, compared with those livers of people who
were homozygous for CYP3A5*3 (Fig. 3). The ratio of 1´-OH
MDZ to 4-OH MDZ is dependent on substrate concentration
and the type of CYP3A enzyme28. At a midazolam concentration
of 8 µM, the ratio was 5.5 when we used recombinant CYP3A4
and 16.1 when we used recombinant CYP3A5. Thus, with liver
microsomes, the observed product ratio depends on the relative
amounts of CYP3A4 and CYP3A5 protein. The average ratio of
1´-OH MDZ to 4-OH MDZ was higher in Caucasian livers with
at least one CYP3A5*1 allele (8.1±3.0 for *1/*3 genotype) than in
those with two CYP3A5*3 alleles (5.9±1.7 for *3/*3; P=0.09). The
Table 2 • CYP3A5 alleles
Starts in Ends in
CYP3A5 exon AC005020* AC005020 5´ splice site 3´ splice site Functional consequence
1 15826 15983 ctatctgtgagtaa
2 19601 19694 ctttgtagatatgg cgtcaggtgagttg
3 21224 21276 tctcccagggtctc gtgggggtgagtat
3B, insertion
from intron 3 22894 23025 tctttca[A/G]tatctc ctaggggtatggat CYP3A5*3- 22893G>A;
insertion of exon 3B into SV1, SV2, SV3; premature
stop after aa 102
4 23130 23229 ccacacagaacgta cgaagggtaagcat
4B, insertion
from intron 4 23931 24036 attcgtagatttgt g[A/G]caggttct CYP3A5*3-insertions of exon 4B into SV2 and SV3
5 28744 28857 aactctagtcttt aaggaggtatgaaa
5B, insertion
from intron 5 28999 29096 atgtacagaaaaga ctacaggtactgat CYP3A5*3-insertion of exon 5B into SV3
6 29120 29208 gtgcttagatgttc gaaagagtaagtag CYP3A5*3-deletion of exon 6 from SV3
7 30495 30643 ccactcagcatctt caataagtatgtgg CYP3A5*6-30597G>A;
deletion of exon 7 from splice variant; frame shift
and premature stop at 184 aa
8 31714 31841 tcccacagtactct caaaaggtaaaatc
9 32927 32993 gcttctagcaccga acaaaggtaaccaa
10 35150 35310 cctttcagctctgt aataaggtgagggg
11 43030 43256 ccttccaggcacca tgaaaggtacaagt
12 45577 45736 ggaactaggttcag acacaggtcagtac
13 47409 47615 tattgtagatcccc
*The accession numbers for the reference CYP3A5*1 cDNA and CYP3A5*3 are J04813 and AC005020, respectively. SV1, splice variant-1; SV2, splice variant-2; SV3,
splice variant-3. CYP3A5*3 has a G at nt 22,893 and a consensus splice site of [tttcAGtatc] and aberrant splicing of CYP3A5 mRNA. CYP3A5*1 contains an A at nt
22,893 generating a sequence of [tttcAAtatc] and no aberrant splicing of CYP3A5 mRNA. To renumber the mutation sites according to the translation start site
(nt 15913 is A in the ATG initiation codon), subtract 15912 bases from the SNP location (for example, the location of CYP3A5*6 is 14685G>A).
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average ratio of 1´-OH MDZ to 4-OH MDZ was
higher in African American livers with at least
one CYP3A5*1 allele (9.8±3.8 for *1/*1,*3,*6
genotypes) than in those with two CYP3A5*3
alleles (8.3±1.6 for *3/*3; P=0.41).
Measurement of CYP3A quantity in the same
47 livers showed that CYP3A4 content was not
significantly different between Caucasian and
African American livers. Within each ethnicity
there was no difference in mean CYP3A4 con-
tent between livers with or without at least one
CYP3A5*1 allele. The amount of total CYP3A in
Caucasian and African Americans was approxi-
mately threefold higher in those with the
CYP3A5*1 allele than in people not carrying
this allele (P=0.001 and P=0.01, respectively).
Moreover, CYP3A5 protein represented more
than 50% of the total CYP3A content in one-
third of Caucasian livers and over one-half of
African American livers. Thus, CYP3A5 repre-
sented a considerably greater proportion of total
CYP3A than previously estimated14 and con-
tributed significantly to CYP3A content and cat-
alytic activity.
Because CYP3A5 is variably expressed in
human intestine16, we took advantage of a
unique cohort of paired samples of small intes-
tine and liver to determine whether the
CYP3AP1*1 genotype-phenotype concordance
is seen in extrahepatic tissues. All people with
large quantities of CYP3A5 in the liver also had
relatively high intestinal levels of CYP3A5 and
were heterozygous or homozygous for the
CYP3A5*1 allele (Fig. 4). Further, the intestinal
midazolam product ratio for people with at least
one CYP3A5*1 allele (9.6±2.5 for the AG genotype) differed from
that for people with two CYP3A5*3 alleles (6.0±0.3; P=0.06).
The CYP3A4*1B allele was originally proposed to be associated
with altered CYP3A4 hepatic activity20,29,30, but this proposal has
been controversial31,32. Because the CYP3A4*1B and CYP3AP1*1
or CYP3A4*1B and CYP3A5*1 alleles can all be present in the
same person, we hypothesized that it is ultimately the CYP3A5
genotype that influences the overall functional activity of
CYP3A. African Americans frequently carried both CYP3AP1*1
and CYP3A4*1B alleles (Table 3), and using data from those peo-
ple homozygous for CYP3A4*1B or CYP3AP1*1, we determined
the linkage of the two alleles (data not shown; χ2=12.8, P<0.001).
The association of the CYP3A5*1 and CYP3A4*1B alleles was not
significant in African Americans, but approached statistical sig-
nificance in Caucasians.
The CYP3A7 promoter contains a set of 7 tightly linked vari-
ants that replaced 60 bp of the CYP3A7 promoter with the identi-
cal region from the CYP3A4 promoter; thus this replacement
altered 3 transcription-factor–binding sites33: hepatic nuclear
factor-5 (HNF-5), an octamer motif and the PXRE. Although
CYP3A7 is generally expressed only during fetal development,
CYP3A7 mRNA is detected in a small fraction of adults13. We
speculated that these nucleotides are important for the increased
expression of hepatic CYP3A4 and loss of CYP3A7 expression in
most people after birth. We evaluated hepatic CYP3A7 mRNA
expression in nine adult livers (five with the variant CYP3A7*1C
allele) to determine whether this replacement of CYP3A7 pro-
moter elements by CYP3A4 sequences is related to expression of
CYP3A7. The two people with the highest levels of CYP3A7
mRNA carried CYP3A7*1C, and four of five people with
CYP3A7*1C alleles expressed CYP3A7 mRNA (data not shown).
One person with the CYP3A7*1C allele had no CYP3A7 mRNA,
however, and two people lacking CYP3A7*1C had very low but
detectable levels of CYP3A7 mRNA. Thus, CYP3A7*1C is associ-
ated with CYP3A7 mRNA expression, but is not the sole explana-
tion for CYP3A7 expression in adults.
Discussion
Our findings show that SNPs in CYP3A5 that cause alternative
splicing and truncation of CYP3A5 protein provide a molecular
explanation for the absence of CYP3A5 protein from some peo-
ple. The most common cause of the loss of hepatic CYP3A5
Fig. 2 Relationship between CYP3A5 phenotype and CYP3A5
genotype in livers of Caucasians (a) and African Americans
(b). Microsomal content of CYP3A5 protein in human livers
(HL) was determined by immunoblot analysis. Identification
of the CYP3AP1 and CYP3A5 genotypes were made by direct
sequencing of genomic DNA: the CYP3AP1*1/*1,
CYP3AP1*1/*3 and CYP3AP1*3/*3 genotypes (GG, AG and
AA, respectively at nt –44 of the CYP3AP1 promoter). The
CYP3A5 genotypes are defined in Fig. 1.
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expression is a SNP at nt 22,893 (AC005020) in intron 3 of
CYP3A5*3; this SNP generates a cryptic splice site and exon 3B.
Splicing of this exon into the CYP3A5*3 transcript introduces a
stop codon. Thus, translation of the abnormal transcript gener-
ates a protein that is prematurely terminated at amino acid 109.
The new CYP3A5*6 allele, which was identified in African
Americans, contained a 30597G>A mutation in exon 7. This
SNP correlates with the deletion of exon 7 from the CYP3A5
mRNA and lower CYP3A5 catalytic activity in three African
Americans. CYP3A5 expression was also closely associated with
the CYP3AP1*1 genotype12,17; however, the CYP3A5 phenotype
was better predicted by CYP3A5 genotype. Comparison of
CYP3AP1*1 and CYP3A5*1 genotypes among the DPDR subset
revealed only 37.5% linkage; in Mexicans, only 65% linkage; and
in Japanese, Southeast Asians, Chinese and Pacific Islanders,
90–95% linkage. Although we detected small amounts of nor-
mally spliced CYP3A5 mRNA and resulting protein even in
those people homozygous for CYP3A5*3, cryptic splices sites
within intron 3 were used preferentially. Thus, only those people
with at least one CYP3A5*1 allele polymorphically express high
amounts of CYP3A5. These results add to the growing list of
splicing alterations that affect the expression of clinically impor-
tant genes34.
In addition to determining the basis for polymorphic CYP3A5
expression, we demonstrated that in people with at least one
CYP3A5*1 allele, the peak hepatic content of CYP3A5 is much
higher than previously thought24,35 and is approximately the same
as the reported peak level of CYP3A4 (ref. 8). For most Caucasians
and African Americans who carry the CYP3A5*1 allele, we also
found that CYP3A5 accounts for at least 50% of the total CYP3A
content. Thus, CYP3A5 should contribute substantially to the total
metabolic clearance of the many CYP3A substrates. Indeed, we
predict that people with the highest clearance and lowest oral
bioavailability of CYP3A substrates will be heterozygous or
homozygous for CYP3A5*1. These people might be more likely to
encounter a lack of efficacy from a standard dose of active parent
drug. Moreover, because CYP3A4 and CYP3A5 have varying
degrees of catalytic capability and regioselectivity toward some
substrates and because CYP3A4 and CYP3A5 are differentially
inhibited by some compounds,
polymorphic CYP3A5 expres-
sion will contribute to differ-
ences in metabolite profiles and
in susceptibility to inhibitory
drug interactions. One can also
envision an increased risk of
adverse effects from CYP3A5-
generated toxic metabolites in
people that predominantly
express CYP3A5. For instance,
the rate of 3α-hydroxylation of
aflatoxin B1 (the inactivation
step) by CYP3A5 is approxi-
mately 1% of that of CYP3A4,
whereas CYP3A5 efficiently cat-
alyzes the 8,9-epoxidation (the
activation step) of aflatoxin B1
(ref. 36). Thus, in those for
whom CYP3A5 is the dominant hepatic CYP3A, the relative lack of
aflatoxin B1 detoxification compared to activation of this agent
might enhance the genotoxicity of aflatoxin36. Because polymor-
phic CYP3A5 is one factor contributing to individual variation in
CYP3A-mediated metabolism of drugs14,35, simple DNA-based
tests can now be used to determine how individual differences in
CYP3A5 contribute to the overall metabolic fate of these 
CYP3A substrates, to their pharmacodynamic variability and to
disease risk.
CYP3A5 is the primary CYP3A family member expressed out-
side the liver and intestine (for example, kidney, lung and poly-
morphonuclear leukocytes), indicating that CYP3A5 has an
important physiologic function in these tissues. Indeed, CYP3A5
can mediate the metabolism of cortisol to 6β-hydroxycortisol, a
physiologic regulator of Na+ transport in renal epithelia37. Vari-
able and polymorphic renal expression of CYP3A5 (refs. 38,39)
may contribute to individual differences in the localized genera-
tion of 6β-hydroxycortisol within the nephron and may have an
etiologic role in, for example, salt-sensitive hypertension by
increasing renal retention of Na+. Thus, CYP3A5 is not just a cat-
alyst of drug detoxification, but, in organs such as the kidney, it
may serve an important function in regulating the pool of
endogenous paracrine or endocrine factors. Similarly, polymor-
phic expression of CYP3A5 may contribute to variable metabo-
lism of steroids in the prostate and breast, to differences in the
concentrations of circulating steroids and, hence, to risk of dis-
ease in these tissues.
Among the Caucasians and African Americans studied here, the
CYP3A5*1 genotype was associated with significant levels of
CYP3A5 protein in the liver and small intestine, the two main tissues
in which CYP3A5 is likely to make the greatest contribution to drug
elimination. The polymorphic distribution of the CYP3A5*1 allele
indicates that relatively high levels of metabolically active CYP3A5
are expressed by an estimated 30% of Caucasians, 30% of Japanese,
30% of Mexicans, 40% of Chinese and more than 50% of African
Americans, Southeast Asians, Pacific Islanders and Southwestern
American Indians. The higher prevalence of CYP3A5 expression
indicates that these non-Caucasians are more likely to experience
higher clearance of drugs principally inactivated by CYP3A; are less
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Fig. 3 Rates of midazolam hydroxyla-
tion in livers with different CYP3A5
genotypes. Total rate of midazolam
hydroxylation in liver microsomes was
measured. The CYP3A5 genotypes are
defined in Figs. 1 and 2. Bars indicate
mean values for the subpopulations.
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likely to experience dose-limit-
ing toxicities; and have different
risks of diseases that are associ-
ated with the CYP3A5 expressor
phenotype. Natural selection
could drive the high frequency of CYP3A5*1 alleles in African Amer-
icans and equatorial ethnic groups if, for example, there was a causal
link between CYP3A5 expression and renal metabolism of endoge-
nous molecules that affect Na+ retention37. Such a link might confer
a selective advantage in areas of water shortage.
Using the CYP3A4*1B allele as a marker, several investigators
have postulated that CYP3A4 is a candidate gene in the develop-
ment of several disorders including prostate cancer and
epipodophyllotoxin-induced secondary acute myelogenous
leukemia20,29,30. Our finding of the simultaneous occurrence of
CYP3A4*1B, CYP3AP1*1 and CYP3A5*1 alleles in some people
indicates the need to re-evaluate this association and to deter-
mine whether the CYP3A5 genotype and CYP3A5 expression are
more closely associated with these disease risks.
Data on the frequencies of SNPs in human genes have been
largely gathered from surveys of exons and introns40,41, with little
specific attention given to the frequency of SNPs in upstream reg-
ulatory regions, particularly those of differentially regulated gene
family members. Previous studies have reported a nucleotide
diversity of about 1 in 2,000 bp of noncoding DNA (consisting
mostly of 5´ and 3´ UTRs and introns) and lower frequencies in
coding sequences; the least frequent SNP, with a nucleotide diver-
sity of approximately 1 in 20,000 bp, was a coding SNP that
causes a nonconservative amino acid substitution41. In Cau-
casians, the observed nucleotide diversity in the CYP3A4 pro-
moter was 1 in 7,246 bp; in the CYP3AP1 promoter, 1 in 2,577 bp;
in the CYP3A5 promoter, 1 in 3,175 bp; and in the CYP3A7 pro-
moter, 1 in 4,444 bp. In African Americans the observed
nucleotide diversity in the CYP3A4 promoter was 1 in 1,000 bp;
in the CYP3AP1 promoter, 1 in 649 bp; in the CYP3A5 promoter,
1 in 2,841 bp; and in the CYP3A7 promoter, 1 in 1,677 bp. It will
be of interest to compare the level of nucleotide diversity within
the CYP3A promoters with a much larger diverse survey of
human gene promoters.
Traditionally, pharmacoge-
netics research used the strat-
egy of identifying outliers in
drug response, obtaining the
DNA from outliers and identi-
fying sequence variation in
genes involved in that drug’s
metabolism. In the post-
genomic era, reverse pharma-
cogenetics approaches are
under way in which common
polymorphisms are first identified in panels of DNA from anony-
mous people and then screening for these common sequence
variations is carried out in people whose drug metabolism phe-
notype is known. For genes of pharmacogenetic interest, or for
any gene, the fewer the number of DNA samples required to
detect these common genetic variants, the more rapidly and cost
effectively common variants can be identified. Moreover, these
common variants are proposed to significantly contribute to
risks of common disease4. Our results confirm that the smallest
subset of eight DPDR samples was sufficient to identify all com-
mon polymorphisms in the CYP3A promoters and in the gene
CYP3A5, including two polymorphisms that had a high proba-
bility of being missed in a random population sample of 25 peo-
ple. This result indicates the robust power of this resource for
rapid SNP discovery.
Methods
Population samples. We sequenced the CYP3A promoters of 159 people.
Eight samples were from the DPDR (Coriell Cell Repositories). We also
obtained samples from the following sources: 47 livers (27 Caucasian
donors, 20 African American donors) whose midazolam 1´-hydroxylase
and 4-hydroxylase activities and CYP3A5 and CYP3A4 protein were char-
acterized (University of Washington, University of Pittsburgh, the Medical
College of Virginia and St. Jude Children’s Research Hospital); primary
human hepatocytes from 8 people whose basal and drug-inducible testos-
terone 6β-hydroxylase activity had been characterized (University of Pitts-
burgh); kidneys from 12 people (Indiana University); 29 subjects (repre-
sentatives of 7 families) whose nifedipine clearance had been determined
(University of Newcastle upon Tyne, UK); 5 family members, one of whom
was a poor nifedipine metabolizer (University of Michigan); 12 pediatric
patients (St. Jude Children’s Research Hospital); 14 subjects whose hepatic
CYP3A phenotype had been determined by using the erythromycin breath
test (University of Michigan); 10 subjects whose intestinal CYP3A4 content
had been determined (University of Michigan); hepatocytes from 10 peo-
ple for whom the drug induction of CYP3A protein had been characterized
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Fig. 4 Association between CYP3A5
expression and CYP3A5 genotype in
human liver and small intestine.
Eleven pairs of tissue obtained from
the same donors (all Caucasian) were
analyzed for CYP3A5 protein content;
the CYP3AP1 and CYP3A5 genotypes
are defined in Figs. 1 and 2. CYP3A5
content ranged from undetectable
levels to 31 pmol/mg of intestinal
homogenate protein. NA, not avail-
able. Intestine ratio=1´-OH MDZ for-
mation (pmol/min/mg)/4-OH MDZ
formation (pmol/min/mg). Low activ-
ity, less than 25 pmol 1´-OH MDZ per
min per mg homogenate protein
(limit of quantitation).
Table 3 • Presence of CYP3A4*1B and CYP3AP1*1 or CYP3A4*1B and CYP3A5*1 in one person
At least one At least one
Caucasians CYP3AP1*3/*3 CYP3AP1*1 allele CYP3A5*3/*3 CYP3A5*1 allele
CYP3A4*1/*1 63 10 14 3
CYP3A4*1B 1 2 0 2
African Americans
CYP3A4*1/*1 11 3 3 3
CYP3A4*1B 3 15 2 9
CYP3AP1 and CYP3A4 genotypes: Caucasians, χ2=6.08; P=0.01; African Americans, χ2=12.26; P=0.0004. CYP3A4 and
CYP3A5 genotypes: Caucasians, Fishers exact test P=0.058; African Americans, Fishers exact test P=0.28.
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(INSERM and Medical College of Virginia); 11 pairs of small intestine and
liver (some liver samples are the same as those mentioned above) and
intestines of 3 Caucasians whose midazolam 1´-hydroxylase and 4-hydrox-
ylase activities and CYP3A5 protein had been characterized (University of
Washington). We sequenced the CYP3AP1 promoter and CYP3A5 introns
3, 4 and 6 in samples from 10 Mexicans, 9 Japanese, 10 Chinese, 10 South-
east Asians, 6 Pacific Islanders and 5 Southwestern American Indians
(Human Variation Panels, Coriell Cell Repositories). Informed consent
was obtained from all people and approval of this research was obtained
according to the relevant institutional guidelines.
Primers and sequencing. We used primer3 (http://www.genome.
wi.mit.edu/cgi-bin/primer/primer3.cgi) to design primers to amplify the
promoter regions of CYP3A4, CYP3A5, CYP3AP1 and CYP3A7; the ampli-
cons were 400–600 bp. The sequences of the primers were as follows:
CYP3A4, 5´–TGGGATGAATTTCAAGTATTTTG–3´ (f) and
5´–AGGTTTCCATGGCCAAGTCT–3´ (r); CYP3A4 primers to sequence
the distal PXRE sequences (nt –7,836 to –7,208), 5´–CCGATCA-
GAATAAGGCATTG–3´ (f) and 5´–GATTCACCTGGGGTCAACAC–3´ (r);
CYP3AP1 primers, 5´–GGGGATGGATTTCAAGTATTCTG–3´ (f) and
5´–GTCCATCGCCACTTGCCTTCT–3´ (r); CYP3A7 primers, 5´–GTCTG-
GCTGGGTATGAAAGG–3´ (f) and 5´–GCCAAGTTTGGGATGAGAT–3´
(r); CYP3A5, 5´–GAGGATGGATTTCAATTATTCTA–3´ (f) and 5´–GTC-
CATCGCCACTTTCCTTC–3´ (r). Forward and reverse primers were tailed
with universal sequencing primers (–40 M13 and –28 M13, respectively).
Primer pairs were used for 35 cycles to amplify genomic DNA. The follow-
ing conditions were used in each cycle: 95 °C for 15 s, 61 °C for 30 s, and 72
°C for 5 min. We removed unincorporated nucleotides and primers by
incubating the PCR product with shrimp alkaline phosphatase and exonu-
clease for 30 min at 37 °C followed by 15 min at 80 °C (ref. 42). Primers for
amplification of the full-length CYP3A5 cDNA were P1, 5´–AACAGCCCA
GCAAACAGCAGC–3´ (f), and P2, 5´–TAAGCCCATCTTTATTTCAAGGT
–3´ (r). Primers for sequencing the CYP3A5 cDNA were as follows: P3,
5´–GTTGCTATTAGACTTGAGAGGACT–3´; P4, 5´–TGTAAGGATCTAT
GCTGTCCTTC–3´; P5, 5´–CACAAATCGAAGGTCTTTAGGC–3´; P6,
5´–TCAAAAACTGGGGTAAGGAATG–3´; P7, 5´–GCCTAAAGACCTTC
GATTTGTG–3´; P8, 5´–CATTCCTTACCCCAGTTTTTGA–3´; P9, 5´–AGT
CCTCTCAAGTCTAATAGCAAC–3´; P10, 5´–GAAGGACAGCATAGATC
CTTACA–3´; P11, 5´–CAGGGTCTCTGGAAATTTGACA–3´; P12, 5´–TCA
TTCTCCACTTAGGGTTCCA–3´; and P13, 5´–CAGCATGGATGTGAT
TACTGGC–3´. The primers used to amplify CYP3A5 exon 3B, 4B and 5B
insertions from genomic DNA were 5020_22719, 5´–CCTGCCTT
CAATTTTTCACTG–3´ (f), and 5020_24161, 5´–GCAATGTAGGAAG-
GAGGGCT–3´ (r). The nested primers used to sequence the nt 22,893 site
were 5020_22743, 5´–TAATATTCTTTTTGATAATG–3´ (f), and 5020_23205,
5´–CATTCTTTCACTAGCACTGTTC–3´ (r). The nested sequencing primers
used to sequence the nt 24,035 site were 5020_23761, 5´–CAACAAAAACCG
GCAAACTG–3´ (f), and 5020_24135, 5´–AGGATTTTCAGACTTAA
CAC–3´ (r). The primers used to amplify the exon 7 deletion in CYP3A5*6
were 5020_28814, 5´–GGTCATTGCTGTCTCCAACC–3´ (f), and the P6
primer (r), and to sequence across exon 7 5020_30237, 5´–TAT
GACTGGGCTCCTTGACC–3´ (f), and 5020_30745, 5´–TGGAATTGTAC
CTTTTAAGTGGA–3´ (r).
We sequenced the proximal promoters by performing standard fluores-
cence-based sequencing with Amersham ET Dye Primers. The distal pro-
moter region of CYP3A4 and the CYP3A5 promoter were sequenced by
using BigDye Terminator sequencing, and products were resolved by poly-
acrylamide gel electrophoresis or by capillary gel electrophoresis. The
resultant trace files were base-called by phred and assembled by phrap
(http://www.genome.washington.edu). Polyphred42 was used to detect
potential heterozygosity. To be a true variant, the variant-containing
sequence generated by the forward primer had to be identical to that gener-
ated by the reverse primer.
Western-blot analysis. We performed quantitative immunoblotting of
CYP3A5 and CYP3A4 content of tissue preparations as described16; puri-
fied cDNA-expressed CYP3A5 (a gift from R. Peter) and CYP3A4 purified
from human liver were the reference standards11. Liver microsomes (10–20
µg) and intestinal homogenates (50 µg), both of which had been prepared
from organ donor tissue16, were resolved by electrophoresis, and CYP3A5
was detected with anti-CYP3A5 antibody (Gentest) or anti-CYP3A4 anti-
body16. We determined the integrated optical density of each band by using
a ChemiDoc (Biorad) and Quantity One program.
Midazolam kinetic protocol. Midazolam, 15N3-midazolam, 1´-OH
MDZ and 4-OH MDZ were provided by Roche Laboratories. All incuba-
tions were performed in duplicate in solutions containing potassium
phosphate (0.1 M, pH 7.4) and human liver microsomes (20–100 µg) or
intestinal homogenates (50–100 µg) or recombinant CYP3A4 or
CYP3A5 (10 pmol; Gentest). Midazolam (final concentration, 8 µM)
was added to the diluted tissue preparations, and the mixtures were
preincubated at 37 °C for 5 min. We added NADPH (final concentra-
tion, 1 mM) to initiate the reaction. Incubation of human liver micro-
somes lasted for 2 min; incubation of recombinant CYP3A and intestinal
samples lasted for 4 min. Reactions were terminated by the addition of 1
ml of ice-cold Na2CO3 (0.1 M, pH ∼11). We used NCI GC-MS to mea-
sure the quantities of extracted 1´-OH MDZ and 4-OH MDZ (ref. 16).
Reaction velocities and product ratios are presented as mean±s.d. Statis-
tical comparisons of mean data for different genotypes were performed
by using a 2-sided, unpaired t-test with unequal variances.
RT–PCR of CYP3A7. Total RNA (5–10 µg) from human liver was reverse-
transcribed according to the manufacturer’s instructions (Life Technolo-
gies). CYP3A7 cDNA was amplified from first-strand cDNA using 
oligonucleotides CYP3A7(S), 5´–ATTCCAAGCTATGTTCTTCATCAT–3´,
and CYP3A7(AS), 5´–AATCTACTTCCCCAGCACTGA–3´, under described
conditions43, except the initial denaturation lasted 5 min, the annealing tem-
perature was 58 oC and the reaction required 25 cycles. The PCR product was
analyzed on agarose gels. Amplification of 28S rRNA served as a control for
RNA integrity.
GenBank accession numbers. CYP3AP promoter, S74700; CYP3AP1*1
promoter consensus sequence, AF35929. Sequences of CYP3A5*3 alterna-
tively spliced exons, AF355800, AF 355804, AF355801 and AF355802, and
CYP3A5*6, AF355803.
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